At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 50 enrolled
Drug / intervention
TEV-48125 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Open-label Trial Evaluating the Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
In Brief
A Phase 3 clinical trial evaluating TEV-48125 for Migraine. Completed, enrolled 50 participants across 1 site.
Detailed Summary
To evaluate the long-term safety and tolerability of subcutaneous (SC) administration of TEV-48125 (at 225 mg once monthly \[except for a loading dose of 675 mg for CM patients\] or at 675 mg every 3 months) for the preventive treatment of Chronic Migraine and Episodic Migraine patients
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedOct 2017
Enrollment StartDec 2017
Primary CompletionJun 2020
TodayJul 2026
First PostedOct 5, 2017
Enrollment StartDec 7, 2017
Primary CompletionJun 16, 2020
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 8.7 years ago
Interventions
TEV-48125drug
TEV-48125 will be administered subcutaneously once every 4 weeks.
TEV-48125drug
TEV-48125 will be administered subcutaneously once every 12 weeks.